Phase II Study of Combined Treatment with Irinotecan and S-1 (IRIS) in Patients with Inoperable or Recurrent Advanced Colorectal Cancer (HGCSG0302)-Reference-Cited by-同舟云学术

Phase II Study of Combined Treatment with Irinotecan and S-1 (IRIS) in Patients with Inoperable or Recurrent Advanced Colorectal Cancer (HGCSG0302)

Published:2011 Issue:1-2 Volume:80 Page:70-75
ISSN:1423-0232
Container-title:Oncology
language:en
Short-container-title:Oncology

Author:

Komatsu Yoshito,Yuki Satoshi,Sogabe Susumu,Fukushima Hiraku,Iwanaga Ichiro,Kudo Mineo,Tateyama Miki,Meguro Takashi,Uebayashi Minoru,Saga Akiyoshi,Sakata Yuh,Asaka Masahiro

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,General Medicine

Reference23 articles.

1. FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study

2. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

3. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

4. Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

5. Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase II study of S-1 and irinotecan combination therapy in EGFR-mutated non-small cell lung cancer resistant to epidermal growth factor receptor tyrosine kinase inhibitor: North Japan Lung Cancer Study Group Trial 0804 (NJLCG0804);Medical Oncology;2022-08-16

2. A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study;Cancer Chemotherapy and Pharmacology;2018-04-11

3. Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer;British Journal of Cancer;2017-01-12

4. S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102);INT J CLIN ONCOL;2016

5. Oral drugs in the treatment of metastatic colorectal cancer;Expert Opinion on Pharmacotherapy;2016-05-23